We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 05, 2020

Prior Chemoradiotherapy-Related Variables and Outcomes With Durvalumab in Unresectable Stage III NSCLC

Lung Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Impact of Prior Chemoradiotherapy-Related Variables on Outcomes With Durvalumab in Unresectable Stage III NSCLC (PACIFIC)
Lung Cancer 2020 Nov 26;[EPub Ahead of Print], C Faivre-Finn, DR Spigel, S Senan, et al

Further Reading